Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Hybrigenics    ALHYG   FR0004153930

HYBRIGENICS (ALHYG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on HYBRIGENICS
10/10 HYBRIGENICS : rsquo; compound inhibits Ubiqitin-Specific Protease 10 (USP10) and..
09/11 HYBRIGENICS : Télécharger le document associé Meet Hybrigenics Pharma at SOHO 20..
06/07 HYBRIGENICS : gets European patent protection for inhibitors of Ubiquitin-Specif..
04/29 HYBRIGENICS : full year 2016 results
03/14 HYBRIGENICS : Strategic refocusing on biopharmaceutical R&D
02/09 HYBRIGENICS : Encouraging preliminary results of the Phase II clinical study of ..
01/27 HYBRIGENICS' : patent estate of inhibitors of ubiquitin specific proteases conti..
2016 HYBRIGENICS : rsquo; inecalcitol strengthens key patent protection in the United..
2016 HYBRIGENICS : receives green light for a double-blind placebo-controlled Phase I..
2014 HYBRIGENICS : 2014 first-half results and highlights
2014 HYBRIGENICS : successfully raised € 4.6 million
2014 HYBRIGENICS : invests in its genomic capabilities
2014 HYBRIGENICS' : patent estate of inhibitors of ubiquitin-specific proteases is ex..
2014 HYBRIGENICS : revenus et trésorerie au premier semestre 2014
2013 HYBRIGENICS : Hybrigenics' General Meeting highlights - Focus on inecalcitol rec..
2013 HYBRIGENICS : Update on the clinical study of inecalcitol in chronic lymphocytic..
2013 HYBRIGENICS : Hybrigenics' technology platform applied to the study of the aging..
2013 HYBRIGENICS : Hybrigenics' Technology Platform Successfully Applied to the Study..
2013 HYBRIGENICS : 2012 revenues and update on the clinical study of inecalcitol in c..
2013 HYBRIGENICS : launches a new service to screen interactions between small molecu..
2012 HYBRIGENICS : green ligt for two European patents protecting new oral formulatio..
2012 HYBRIGENICS : launches a new website
2012 HYBRIGENICS : Hybrigenics' first half 2012 revenues of EUR 2 million at the same..
2012 HYBRIGENICS : Hybrigenics' General Meeting Highlights
2012 HYBRIGENICS : Bryan, Garnier & Co initiates coverage of Hybrigenics with a targe..
2012 HYBRIGENICS : Bryan Garnier initiates coverage of Hybrigenics with a target pric..
2012 HYBRIGENICS : completed its private placement to institutional investors up to E..
2012 HYBRIGENICS : gets approval and financing for a phase II clinical trial of oral ..
Financials (€)
Sales 2017 1,25 M
EBIT 2017 -5,70 M
Net income 2017 -6,92 M
Finance 2017 8,74 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 12,5x
EV / Sales 2018 7,28x
Capitalization 24,3 M
Chart HYBRIGENICS
Duration : Period :
Hybrigenics Technical Analysis Chart | ALHYG | FR0004153930 | 4-Traders
Technical analysis trends HYBRIGENICS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 1,32 €
Spread / Average Target 155%
EPS Revisions
Managers
NameTitle
Rémi Delansorne Chief Executive Officer & Director
Alain Munoz Chairman
Guillaume Floch Chief Financial Officer
Jean-François Dufour-Lamartinie Head-Clinical Research & Development
Piet Serrure Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HYBRIGENICS-36.77%29
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.15%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538